top of page
Genero Consulting
Executive Management
Biotic Growth
References
About Us
Cureus
​ -
2025 Sep 12
PMID: 41089100 PMCID: PMC12516643 DOI: 10.7759/cureus.92160
Adjunctive Use of PerioCream Following Scaling and Root Planing: Preliminary Findings From an Observational Clinical Study.
MLBON
EURONEXT ACCESS
Euronext Access Paris - BE6333353298 - Stock
15 Oct 2025 15:23 CEST
bonyf AG receives the EU-MDR Certification Class IIa for PerioCream
05 Sep 2025 10:51 CEST
bonyf NV Cancels Planned Capital Increase Following Positive Strategic Developments
11 Aug 2025 15:16 CEST
Periocream: The Future Commercial Winner for bonyf
03 Jun 2025 17:28 CEST
bonyf Welcomes Group Pharmaceuticals as Strategic Stakeholder to Drive Growth in India
15 May 2025 18:11 CEST
bonyf NV Announces First Exports to the United States with Honest Pharma, Marking a Key Milestone in USA Growth Strategy
08 Apr 2025 10:17 CEST
bonyf Advances to Phase 3 in the Development of Alginate-Organic Denture Fixative Cream
13 Mar 2025 13:45 CET
bonyf recently secures its EU Patent, US patent pending, for PerioTabs® & PerioCream, launch in March 2025 at the IDS Cologne
18 Feb 2025 12:24 CET
bonyf Announces Plans for Dual Listing on Nasdaq and Euronext Paris with a Five-Step Strategy
30 Jan 2025 23:21 CET
bonyf R&D presents its two latest innovations at IDS 2025 in Cologne
bottom of page
